Published by Josh White on 4th September 2025
(Sharecast News) - Oxford BioDynamics said on Thursday that interim results from its ongoing FDA-registered PROWES trial demonstrated that its EpiSwitch CiRT test had a significant impact on treatment decisions for cancer patients receiving immune checkpoint inhibitors.
URL: http://www.digitallook.com/dl/news/story/35331370/...